OptimizeRx Co. (NASDAQ:OPRX) Short Interest Update

OptimizeRx Co. (NASDAQ:OPRX) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 561,900 shares, an increase of 27.6% from the July 31st total of 440,200 shares. Based on an average trading volume of 128,300 shares, the short-interest ratio is currently 4.4 days. Currently, 4.8% of the shares of the company are short sold.

Shares of NASDAQ:OPRX traded down $0.51 during trading on Friday, reaching $15.66. 74,800 shares of the stock were exchanged, compared to its average volume of 85,680. OptimizeRx has a 12 month low of $8.92 and a 12 month high of $18.39. The firm has a market cap of $228.93 million, a PE ratio of 313.40, a PEG ratio of 1.81 and a beta of 0.45. The stock has a 50-day moving average price of $15.39 and a 200-day moving average price of $14.34. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.01.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.03 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.03. OptimizeRx had a return on equity of 2.89% and a net margin of 2.27%. The company had revenue of $7.01 million during the quarter, compared to analysts’ expectations of $6.78 million. On average, sell-side analysts expect that OptimizeRx will post 0.22 earnings per share for the current fiscal year.

Several hedge funds have recently modified their holdings of OPRX. BlackRock Inc. boosted its stake in shares of OptimizeRx by 2,111.6% in the second quarter. BlackRock Inc. now owns 607,292 shares of the company’s stock valued at $9,839,000 after buying an additional 579,833 shares during the period. Calamos Advisors LLC bought a new stake in shares of OptimizeRx in the second quarter valued at approximately $4,329,000. 1492 Capital Management LLC boosted its stake in shares of OptimizeRx by 118.8% in the second quarter. 1492 Capital Management LLC now owns 265,185 shares of the company’s stock valued at $4,296,000 after buying an additional 144,006 shares during the period. Park West Asset Management LLC boosted its stake in shares of OptimizeRx by 14.0% in the second quarter. Park West Asset Management LLC now owns 1,088,088 shares of the company’s stock valued at $17,627,000 after buying an additional 133,238 shares during the period. Finally, Avenir Corp boosted its stake in shares of OptimizeRx by 90.9% in the second quarter. Avenir Corp now owns 224,100 shares of the company’s stock valued at $3,630,000 after buying an additional 106,700 shares during the period. Institutional investors and hedge funds own 52.76% of the company’s stock.

Separately, Zacks Investment Research upgraded OptimizeRx from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a report on Wednesday, August 14th.

OptimizeRx Company Profile

OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.

Further Reading: What Factors Can Affect Return on Equity?

Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.